Evidence map›Paper›PMID 33507453›Full record

ArticleJournal of thrombosis and thrombolysis2021

Nonadministration of pharmacologic venous thromboembolism prophylaxis is less common in hospitalized patients with COVID-19.

Mujan Varasteh Kia, Brandyn D Lau, Oluwafemi P Owodunni, Peggy S Kraus, Christine G Holzmueller, Deborah B Hobson, Dauryne L Shaffer, Michael B Streiff, Elliott R Haut

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mujan Varasteh Kia *Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brandyn D Lau *Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Oluwafemi P OwodunniDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Peggy S KrausDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA.
Christine G HolzmuellerThe Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD, USA.
Deborah B HobsonDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dauryne L ShafferDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael B StreiffThe Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD, USA.
Elliott R HautDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ehaut1@jhmi.edu.ORCID http://orcid.org/0000-0001-7075-771X
Johns Hopkins University · USJohns Hopkins Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe incidence of venous thromboembolism (VTE) in patients hospitalized with COVID-19 is higher than most other hospitalized patients. Nonadministration of pharmacologic VTE prophylaxis is common and is associated with VTE events. Our objective was to determine whether nonadministration of pharmacologic VTE prophylaxis is more common in patients with COVID-19 versus other hospitalized patients. MATERIALS AND

methodsIn this retrospective cohort analysis of all adult patients discharged from the Johns hopkins hospital between Mar 1 and May 12, 2020, we compared demographic, clinical characteristics, VTE outcomes, prescription and administration of VTE prophylaxis between COVID-19 positive, negative, and not tested groups.

resultsPatients tested positive for COVID-19 were significantly older, and more likely to be Hispanic, have a higher median body mass index, have longer hospital length of stay, require mechanical ventilation, develop pulmonary embolism and die (all p < 0.001). COVID-19 patients were more likely to be prescribed (aOR 1.51, 95% CI 1.38-1.66) and receive all doses of prescribed pharmacologic VTE prophylaxis (aOR 1.48, 95% CI 1.36-1.62). The number of patients who missed at least one dose of VTE prophylaxis and developed VTE was similar between the three groups (p = 0.31).

conclusionsIt is unlikely that high rates of VTE in COVID-19 are due to nonadministration of doses of pharmacologic prophylaxis. Hence, we should prioritize research into alternative approaches to optimizing VTE prevention in patients with COVID-19.

Indexed as

ChemopreventionCOVID-19Pulmonary EmbolismVenous ThromboembolismAge FactorsCOVID-19 TestingFemaleHospitalizationHospital MortalityHumansLength of StayMaleMiddle AgedPatient SelectionPractice Patterns, Physicians'Respiration, ArtificialCOVID-19Deep vein thrombosisMissed dosesPulmonary embolismThromboprophylaxisVenous thromboembolism

Identifiers

PMID33507453
PMCPMC7840619
OpenAlexW3124627571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.